Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for ...

Minerva Neurosciences ( (NERV)) has provided an announcement. At its annual meeting of stockholders held on December 22, 2025, Minerva Neurosciences, Inc. secured broad shareholder approval for a ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Minerva ...

MINERVA NEUROSCIENCES ($NERV) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.50 per share, beating estimates of -$1.09 ...

Minerva Neurosciences (NASDAQ:NERV) just reported results for the first quarter of 2024. Minerva Neurosciences reported earnings per share of -$1.13. This was above the analyst estimate for EPS of -$1 ...

A downtrend has been apparent in Minerva Neurosciences (NERV) lately. While the stock has lost 10.3% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in ...

Minerva Neurosciences, Inc (NASDAQ:NERV) are shooting higher after the company bagged a $20 million investment from Boehringer Ingelheim and Federated Hermes Kaufmann Funds via private placement of ...

Minerva Neurosciences (NASDAQ:NERV) just reported results for the second quarter of 2024. Minerva Neurosciences reported earnings per share of -$1.09. This was below the analyst estimate for EPS of ...